All In Biotech

Drug Trial Radar · NCT04404595

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers

Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Oct 23, 2020

Primary completion

Jun 1, 2025

Study completion Sep 1, 2035

Sponsor

Lead sponsor
CARsgen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
May 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 76 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers

Conditions

  • Gastric Cancer
  • Pancreatic Cancer

Interventions

  • CT041Biological

    treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b (Cohort A): Evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in subjects with specified advanced digestive system cancers (STAD, PAAD, or BTC).Time frame: up to year 15
  2. Phase 1b (Cohort A): Identify the recommended Phase 2 dose (RP2D) of CT041 therapy in subjects with advanced STAD, PAAD, or BTC.Time frame: day 0 - day 28
  3. Phase 1b (Cohort A): Identify the maximum tolerated dose (MTD) or maximum administered dose (MAD) of CT041 therapy in subjects with STAD, PAAD, or BTC.Time frame: day 0 - day 28
  4. Phase 1b (Cohort B): Determine the efficacy of CT041 by ORR in subjects with advanced STAD, PAAD, or BTC.Time frame: up to year 15
  5. Phase 2 (Cohort C): Determine the efficacy of CT041 by ORR in subjects with advanced STAD treated at the RP2D.Time frame: up to year 15

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of Southern California

    Los Angeles, California

  • UCSD

    San Diego, California

  • UCSF

    San Francisco, California

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Karmanos Cancer Center

    Detroit, Michigan

  • Mayo Cancer Hospital

    Rochester, Minnesota

  • Northwell Cancer Institute

    New Hyde Park, New York

  • The Mount Sinai Hospital

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Ohio State University

    Columbus, Ohio

  • TX Oncology-Baylor Charles Sammons Cancer Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.